The significance of erb-b2 immunostaining in cervical cancer

Gynecologic Oncology

Volumn 73, Issue 3, 1999, Pages 354-358

  Nevin, James ^a   Laing, David ^a   Kaye, Philip ^a   McCulloch, Tom ^b   Barnard, Rochelle ^a   Silcocks, Paul ^d   Blackett, Tony ^c   Paterson, Mike ^e   Sharp, Frank ^c   Cruse, Peter ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^e NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; ONCOGENE NEU; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADICAL HYSTERECTOMY; SURVIVAL TIME; UTERINE CERVIX CARCINOMA;

EID: 0033019433     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1999.5396     Document Type: Article

References (13)

1. Hayes D F. Should we treat HER, too. J Clin Oncol. 14:1996;697-699.
2. Ravdin P M, Chamness G C. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers - a review. Gene. 159:1995;19-27.
3. Brumm C, Riviere A, Wilckens C, Loning T. Immunohistochemical investigation and Northern blot analysis of c-erbB-2 expression in normal, premalignant and malignant tissues of the corpus and cervix uteri. Virchow Archiv Pathol Anat. 417:1990;477-484.
4. Berchuck A, Rodriguez G, Kamel A, Soper J T, Clarke-Pearson D L, Bast R C. Expression of epidermal growth factor receptor and HER-2/Neu in normal and neoplastic cervix, vulva and vagina. Obstet Gynecol. 76:1990;381-387.
5. Hale R J, Buckley C H, Fox H, Williams J. Prognostic value of c-erb-2 expression in uterine cervical carcinoma. J Clin Pathol. 45:1992;594-596.
6. Kihana T, Tsuda H, Teshima S, Nomoto K, Tsugane S, Sonada T, Matsuura S, Hirohashi S. Prognostic significance of the overexpression of c-erbB-2 protein in adenocarcinoma of the uterine cervix. Cancer. 73:1994;148-153.
7. Costa M J, Walls J, Trelford. c-erbB-2 oncoprotein overexpression in uterine cervix carcinoma with glandular differentiation. Am J Clin Pathol. 104:1995;634-643.
8. Nakano T, Oka K, Ishikawa A, Morita S. Correlation of cervical carcinoma c-erb B-2 oncogene with cell proloiferation perameters in patients treated with radiation therapy for cervical carcinoma. Cancer. 79:1997;513-520.
9. Buckley C H, Fox H. Carcinoma of the Cervix. Anthony P P, MacSween R NM. Recent Advances in Histopathology. 1989;63-78 Churchill Livingstone, London.
10. Roland P Y, Stoler M H, Broker T R. The differential expression of the HER-2/neu oncogene among high-risk human papillomavirus-infected glandular lesions of the uterine cervix. Am J Obstet Gynecol. 177:1997;133-138.
11. Look K Y, Brunetto V L, Clarke-Pearson D L, Averette H E, Major F J, Alvarez R D, Homesley H D, Zaino R J. An analysis of cell type in patients with surgically staged stage IB carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 63:1996;304-311.
12. Hale R J, Wilcox F L, Buckley C H, Tindal V R, Ryder W DJ, Logue J P. Prognostic factors in uterine cervical carcinoma: a clinicopathologic analysis. Int J Gynecol Cancer. 1:1991;19-23.
13. Morris M. Early cervical carcinoma: are two treatments better than one. Gynecol Oncol. 54:1994;1-3.